These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35671845)

  • 1. Biosafety risk assessment and risk control of clinical laboratory in designated hospitals for treating COVID-19 in Chongqing, China.
    Long Y; Chang F; Yang F; Hou Y; Mo Z; Diao Q
    Am J Infect Control; 2022 Sep; 50(9):999-1005. PubMed ID: 35671845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosafety threats of the rapidly established labs for SARS-CoV-2 tests in China.
    Yuan D; Gao W; Liang S; Yang S; Jia P
    Environ Int; 2020 Oct; 143():105964. PubMed ID: 32768807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laboratory Biosafety Considerations of SARS-CoV-2 at Biosafety Level 2.
    Wang K; Zhu X; Xu J
    Health Secur; 2020; 18(3):232-236. PubMed ID: 32522074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening High-Risk Groups and the General Population for SARS-CoV-2 Nucleic Acids in a Mobile Biosafety Laboratory.
    Guo Z; Li L; Song Y; Xu J; Huang J
    Front Public Health; 2021; 9():708476. PubMed ID: 34485233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A survey of laboratory biosafety and protective measures in blood transfusion departments during the COVID-19 pandemic.
    Liu H; Liu L; Zhang J; Shang X; Chen S; Li X; Gui R; Huang R
    Vox Sang; 2021 Jul; 116(6):682-691. PubMed ID: 33529377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergency Biosafety Management Practice in Laboratory of Shelter Hospital.
    Liu YS; Peng DL; Yang J; Chen DY; Jia HB; Yu SY; Chen HH; Chen K; Liu LR
    Curr Med Sci; 2020 Oct; 40(5):985-988. PubMed ID: 32980900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biorisk Management for SARS-CoV-2 Research in a Biosafety Level-3 Core Facility.
    Joseph T; Phyu S; Se-Thoe SY; Chu JJH
    Methods Mol Biol; 2022; 2452():441-464. PubMed ID: 35554920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laboratory biosafety measures involving SARS-CoV-2 and the classification as a Risk Group 3 biological agent.
    Kaufer AM; Theis T; Lau KA; Gray JL; Rawlinson WD
    Pathology; 2020 Dec; 52(7):790-795. PubMed ID: 33070960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosafety measures for preventing infection from COVID-19 in clinical laboratories: IFCC Taskforce Recommendations.
    Lippi G; Adeli K; Ferrari M; Horvath AR; Koch D; Sethi S; Wang CB
    Clin Chem Lab Med; 2020 Jun; 58(7):1053-1062. PubMed ID: 32396137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prevention and control of SARS-CoV-2 infection in clinical laboratories: implementation of contingency plan and postpandemic response strategies].
    Hang J; Sun Z; Li L
    Nan Fang Yi Ke Da Xue Xue Bao; 2020 Apr; 40(4):606-608. PubMed ID: 32895124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. General biosafety measures for laboratory environments, outpatient clinics, medical centers, and veterinary hospitals during the SARS-CoV-2 pandemic.
    Ulsenheimer BC; Pereira DIB; Dos Santos HF; von Laer AE; Tonin AA; da Costa MM; Sangioni LA; de Avila Botton S
    Braz J Microbiol; 2022 Sep; 53(3):1715-1721. PubMed ID: 35352318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosafety Concerns During the Collection, Transportation, and Processing of COVID-19 Samples for Diagnosis.
    Karthik K; Aravindh Babu RP; Dhama K; Chitra MA; Kalaiselvi G; Alagesan Senthilkumar TM; Raj GD
    Arch Med Res; 2020 Oct; 51(7):623-630. PubMed ID: 32948378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Principles and suggestions on biosafety protection of biological specimen preservation during prevalence of COVID-19].
    Zhang X; Sun W; Shang S; Mao J; Fu J; Shu Q; Jiang K
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2020 May; 49(2):170-177. PubMed ID: 32391660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Procedures for Flow Cytometry-Based Sorting of Unfixed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Cells and Other Infectious Agents.
    Reifel KM; Swan BK; Jellison ER; Ambrozak D; Baijer J; Nguyen R; Monard S; Lyon G; Fontes B; Perfetto SP
    Cytometry A; 2020 Jul; 97(7):674-680. PubMed ID: 32488957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of Biosafety Principles in Laboratory Analysis of Clinical Samples from Patients with COVID-19.
    Hussain Gardezi SA; Ikram A
    J Pak Med Assoc; 2020 May; 70(Suppl 3)(5):S48-S51. PubMed ID: 32515375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges in the establishment of a biosafety testing laboratory for COVID-19 in Bangladesh.
    Islam SRU; Akther T; Sultana S; Deb P; Ghosh AK; Nasif MAO; Bhuiyan AH; Jahan M; Nessa A; Munshi SU; Tabassum S
    J Infect Dev Ctries; 2021 Dec; 15(12):1833-1837. PubMed ID: 35044940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis to explain unknown causes of the origins of SARS-COV-2.
    Coccia M
    Environ Res; 2022 Aug; 211():113062. PubMed ID: 35259407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of inactivation procedures for SARS-CoV-2.
    Auerswald H; Yann S; Dul S; In S; Dussart P; Martin NJ; Karlsson EA; Garcia-Rivera JA
    J Gen Virol; 2021 Mar; 102(3):. PubMed ID: 33416462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosafety protection and workflow of clinical microbiology laboratory under COVID-19: A review.
    Zhou W; Zou L; Zhu F; Yang J
    Medicine (Baltimore); 2022 Nov; 101(45):e31740. PubMed ID: 36397385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing SARS-CoV-2 nucleic acid testing capacity during the COVID-19 epidemic in Beijing: experience from a general hospital.
    Wang Q; Zhao X; Yue Z; Bai X; Rao H; Han N; Wang T; Wang H; Jiang B
    Emerg Microbes Infect; 2020 Dec; 9(1):2358-2360. PubMed ID: 33054582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.